Mycobacterium bovis BCG-based vaccines against tuberculosis: Novel developments

Vaccine

Volumn 21, Issue 7-8, 2003, Pages 667-670

  Dietrich, Guido ^a   Viret, Jean Francois ^a   Hess, Jürgen ^b  

^a Berna Biotech AG   (Switzerland)

^b November AG   (Germany)

Author keywords

BCG; Mycobacterium bovis; Tuberculosis

Indexed keywords

BCG VACCINE; POLYSORBATE 80; RECOMBINANT ANTIBODY; TYLOXAPOL;

AGE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM CULTURE; CLINICAL TRIAL; CONFERENCE PAPER; CROSS REACTION; DRUG SAFETY; GENE AMPLIFICATION; GENETIC VARIABILITY; HUMAN; IMMUNOGENICITY; MYCOBACTERIUM BOVIS; PRIORITY JOURNAL; TUBERCULOSIS;

ANIMALS; BCG VACCINE; HUMANS; MYCOBACTERIUM BOVIS; TECHNOLOGY, PHARMACEUTICAL; TUBERCULOSIS, PULMONARY; VACCINES, SYNTHETIC;

EID: 0037472397     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00577-7     Document Type: Conference Paper

References (22)

1. Bloom BR, Fine PEM. The BCG experience: implications for future vaccines against tuberculosis. In: Bloom BR, editor. Tuberculosis: pathogenesis, protection and control. Washington (DC): American Society for Microbiology; 1994. p. 531-57.
2. Calmette A., Guerin C., Negre L., Bocquet A. Sur la vaccination préventive des enfants nouveau-nés contre la tuberculose par le BCG. Ann. Inst. Pasteur. 3:1927;201.
3. Behr M.A., Wilson M.A., Gill W.P., Salamon H., Schoolnik G.K., Rane S.et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science. 284:1999;1520-1523.
4. Fine PEM, Carneira IAM, Milstien JB, Clements CJ. Issues relating to the use of BCG in immunization programmes. Geneva: World Health Organization; 1999.
5. Colditz G.A., Brewer T.F., Berkey C.S., Wilson M.E., Burdick E., Fineberg H.V.et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA. 271:1994;698-702.
6. Hess J., Miko D., Catic A., Lehmensiek V., Russell D.G., Kaufmann S.H. Mycobacterium bovis Bacille Calmette-Guérin strains secreting listeriolysin of Listeria monocytogenes. Proc. Natl. Acad. Sci. U.S.A. 95:1998;5299-5304.
7. Murray P.J., Aldovini A., Young R.A. Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guérin strains that secrete cytokines. Proc. Natl. Acad. Sci. U.S.A. 93:1996;934-939.
8. Wangoo A., Brown I.N., Marshall B.G., Cook H.T., Young D.B., Shaw R.J. Bacille Calmette-Guérin (BCG)-associated inflammation and fibrosis: modulation by recombinant BCG expressing interferon-gamma (IFN-gamma). Clin. Exp. Immunol. 199:2000;92-98.
9. Luo Y., Chen X., Han R., O'Donnell M.A. Recombinant bacille Calmette-Guérin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity. Clin. Exp. Immunol. 123:2001;264-270.
10. Horwitz M.A., Harth G., Dillon B.J., Maslesa-Galic S. Recombinant bacillus Calmette-Guérin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc. Natl. Acad. Sci. U.S.A. 97:2000;13853-13858.
11. Yeremeev V.V., Stewart G.R., Neyrolles O., Skrabal K., Avdienko V.G., Apt A.S.et al. Deletion of the 19-kDa antigen does not alter the protective efficacy of BCG. Tuber. Lung. Dis. 80:2000;243-247.
12. Chambers M.A., Williams A., Gavier-Widen D., Whelan A., Hall G., Marsh P.D.et al. Identification of a Mycobacterium bovis BCG auxotrophic mutant that protects guinea pigs against M. bovis and hematogenous spread of Mycobacterium tuberculosis without sensitization to tuberculin. Infect. Immun. 68:2000;7094-7099.
13. Berthet F.X., Lagranderie M., Gounon P., Laurent-Winter C., Ensergueix D., Chavarot P.et al. Attenuation of virulence by disruption of the Mycobacterium tuberculosis erp gene. Science. 282:1998;759-762.
14. Yuan Y., Crane D.D., Simpson R.M., Zhu Y.Q., Hickey M.J., Sherman D.R. Barry CE3rd. The 16-kDa alpha-crystallin (Acr) protein of Mycobacterium tuberculosis is required for growth in macrophages. Proc. Natl. Acad. Sci. U.S.A. 95:1998;9578-9583.
15. Guleria I., Teitelbaum R., McAdam R.A., Kalpana G., Jacobs W.R., Bloom B.R. Auxotrophic vaccines for tuberculosis. Nat. Med. 2:1996;334-337.
16. Milstien J.B., Gibson J.J. Quality control of BCG vaccine by WHO: a review of factors that may influence vaccine effectiveness and safety. Bull. World Health Organ. 68:1990;93-108.
17. Dubos R.J., Fenner F. Production of BCG vaccine in liquid medium containing Tween 80 and a soluble fraction of heated serum. I. Production and viability of the culture. J. Exp. Med. 91:1950;261-268.
18. Kim T.H. High-viability lyophilized Bacille Calmette-Guérin vaccine produced by deep-culture technique. Appl. Environ. Microbiol. 34:1977;495-499.
19. Gheorghiu M., Lagrange P.H., Fillastre C. The stability and immunogenicity of a dispersed-grown freeze-dried Pasteur BCG vaccine. J. Biol. Stand. 15:1988;15-26.
20. van Hemert PA. BCG vaccine. In: van Hemert PA, editor. Vaccine production as a unit process. PhD thesis. Leiden; 1971. p. 110-6.
21. Nyabenda J., Bautens E., Borremans M., Verhofstadt R., Weckx M., Marchal A. The production of mycobacterial antigens by homogeneous culture in a fermentor. J. Biol. Stand. 16:1988;259-267.
22. Dietrich G., Mollenkopf H.J., Weber H., Diehl K.D., Knapp B., Kaufmann S.H.E.et al. Cultivation of Mycobacterium bovis BCG in bioreactors. J. Biotechnol. 96:2002;259-270.